Apoptosis-mediated antiproliferative activity of friedolanostane triterpenoid isolated from the leaves of Garcinia celebica against MCF-7 human breast cancer cell lines
- Authors:
- Published online on: October 15, 2015 https://doi.org/10.3892/br.2015.532
- Pages: 79-82
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The leaves of Garcinia celebica strongly inhibit the proliferation of MCF‑7 human breast adenocarcinoma cell lines. The present study focused on investigating the active anticancer and antiproliferative compound from the G. celebica leaves and assessing its mechanism of action. Ethanol extracts of G. celebica were fractionated based on their polarity using n‑hexane, ethyl acetate and water. The antiproliferative properties were tested in vitro against MCF‑7 human breast cancer cell lines using the 3‑(4,5‑dimethylthiazolyl‑2)‑2,5‑diphenyltetrazolium bromide assay. The active compound was subsequently isolated using column chromatography and identified by nuclear magnetic resonance. The characterized compound was also tested for its antiproliferative properties and the mechanism by which it induces apoptosis in MCF‑7 cells by western blot analysis of the activated apoptotic proteins. This resulted in the isolation of a friedolanostane triterpenoid, which was determined to be methyl‑3α,23‑dihydroxy‑17,14‑friedolanstan‑8,14,24‑trien‑26‑oat. This compound inhibited MCF‑7 cell proliferation in a time‑ and dose‑dependent manner with IC50 values of 82 and 70 µM for the 24 and 48 h treatments, respectively. Furthermore, the western blot analysis suggested that the compound exerted its anticancer activities by promoting apoptosis through the inhibition of the oncogenic protein Akt, thereby increasing the expression of poly (ADP‑ribose) polymerase (PARP) protein. These results suggest that methyl‑3α,23‑dihydroxy‑17,14‑friedolanstan‑8,14,24‑trien‑26‑oat is the anticancer compound found in G. celebica, providing a basis for its potential use in cancer disease management.
